; and (III) appropriate directions and warnings concerning storage and handling. (B) Inapplicability of exclusivity provisions (i) No exclusivity for a certified medical cannabis product. No designated State medical cannabis product deemed under subparagraph (A)(i) to have in effect an approved application is eligible for any period of exclusivity for a new drug under section 355(c), 355(j), or 360cc of this title, or the extension of any such period under section 355a of this title, on the basis of such deemed approval. (ii) Effect on certification No period of exclusivity under section 355(c), 355(j), or section 360cc of this title, or the extension of any such period under section 355a of this title, with respect to an application for a drug product, shall prohibit, limit, or otherwise affect the submission, grant, or effect of a certification under this section, except as provided in subsection (a)(3)(A)(i)(VIII) and section 360ddd(1)(H) of this title. (4) Withdrawal, suspension, or revocation of approval (A) Withdrawal, suspension of approval Nothing in this part limits the Secretary’s authority to withdraw or suspend approval of a drug product, including a designated State medical cannabis product deemed under this section to have in effect an approved application under section 355 or section 360b of this title. (B) Revocation of certification The Secretary may revoke the grant of a certification under paragraph (2) if the Secretary determines that the request for certification contains any material omission or falsification. (5) Prescription or recommendation requirement for designated state medical cannabis products (A) In general A designated State medical cannabis product is not approved for use without a prescription by a qualified medical professional or a recommendation by a qualified medical professional as defined by the law of the State in which the qualified medical professional is providing said prescription or recommendation. (B) Labeling For medical cannabis products provided pursuant to